Association of age with survival in @entity1 with metastatic XXXX : analysis from the ARCAD Clinical Trials Program.

@entity1 @entity204 @entity14 @entity1349
PURPOSE: This study addressed whether age is prognostic for @entity1349 ( @entity1349 ) or @entity1349 ( @entity1349 ) in @entity1 with metastatic @entity14 (mCRC). @entity1 AND METHODS: A total of 20,023 @entity1 from 24 first-line clinical trials in the ARCAD (Aide et Recherche en Canc  rologie Digestive) database were analyzed. Primary age effects and interactions with age,sex, performance status (PS), and metastatic site were modeled using Cox proportional hazards stratified by treatment arm within study. RESULTS: Of total @entity1 , 3,051 (15%) were age < or =50 years. Age was prognostic for both @entity1349 (P < .001)and @entity1349 (P < .001), with U-shaped risk (i.e., highest risk was evident in youngest and oldest @entity1 ). Relative to @entity1 of middle age, the youngest @entity1 experienced 19% (95% CI, 7% to 33%) increased risk of @entity204 and 22% (95% CI, 10% to 35%) increased risk of progression. The oldest @entity1 experienced 42% (95% CI, 31% to 54%) increased risk of @entity204 and 15% (95% CI, 7% to 24%) increased risk of progression or @entity204 . This relationship was more pronounced in the first year of follow-up. Age remained marginally significant for @entity1349 (P = .08) when adjusted forPS, sex, and presence of liver, lung, or peritoneal metastases, and age was significant in an adjusted model for @entity1349 (P = .005). The age effect did not differ by site of metastatic disease, year of enrollment, type of therapy received, or biomarker mutational status. CONCLUSION: Younger and older age are associated with poorer @entity1349 and @entity1349 among treated @entity1 with mCRC. Younger and older @entity1 may represent higher-risk populations, and additional studies are warranted.
